Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer
Journal of Health Economics and Outcomes Research · 29.07.2025 · 12 (2)
DOI: 10.36469/001c.141170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health Economics and Outcomes Research, online erschienen am 29.07.2025. Verfasst von Shawn Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Horsham, Pennsylvania. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prostate-specific antigen (PSA) has been used as both a screening tool and a marker for treatment response for advanced prostate cancer. With the introduction of androgen receptor pathway inhibitor (ARPI)-based treatment for metastatic castration-sensitive prostate cancer (mCSPC), there is a need to understand the impact that early treatment response, as measured by PSA, has on long-term clinical outcomes.
Objectives
To assess whether long-term indicators of treatment success differ among ARPI-naïve patients with mCSPC who did or did not attain ≥90% reduction in PSA levels within 6 months of treatment initiation.
Methods
Patients with mCSPC initiating a first ARPI (ie, apalutamide, enzalutamide, abiraterone acetate, darolutamide) were identified using electronic medical record data linked to insurance claims in the United States (1/1/2016–9/30/2022). Eligible patients were classified based on whether they achieved ≥90% reduction in PSA measured between pre-treatment and a window of 30 to 180 days after ARPI initiation. Cohorts were balanced using inverse probability of treatment weighting. Weighted Kaplan-Meier analysis was used to compare overall survival and castration-resistance–free survival by 36 months post-index between those with and without ≥90% PSA reduction.
Results
Weighted cohorts included 1192 patients with early PSA reduction ≥90% and 699 without. By 36 months, significantly better overall survival was observed in those with early PSA reduction ≥90% than in those without (71.5% vs 54.7%; hazard ratio [HR]: 0.40, 95% confidence interval [CI]: 0.31, 0.50; P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Johnson & Johnson, Horsham, Pennsylvania.
- Analysis Group, Inc., Montréal, Québec, Canada.
Zitieren
APA
Du, S., Rossi, C., Khilfeh, I., Boonmak, P., Wong, G., Pilon, D., & Ellis, L. (2025). Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer. Journal of Health Economics and Outcomes Research, 12(2). https://doi.org/10.36469/001c.141170
Vancouver
Du S, Rossi C, Khilfeh I, Boonmak P, Wong G, Pilon D, et al. Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer. Journal of Health Economics and Outcomes Research. 2025;12(2). doi:10.36469/001c.141170
BibTeX
@article{Du2025,
author = {Du, Shawn and Rossi, Carmine and Khilfeh, Ibrahim and Boonmak, Porpong and Wong, Gordon and Pilon, Dominic and Ellis, Lorie},
title = {Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer},
journal = {Journal of Health Economics and Outcomes Research},
year = {2025},
volume = {12},
number = {2},
doi = {10.36469/001c.141170}
}
EUVIMED